ALX Oncology Achieves 92% Complete Response in Non-Hodgkin Lymphoma with Evorpacept Combination
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 10 hour ago0mins
- Clinical Trial Success: ALX Oncology's Phase 2 trial demonstrates that the combination of evorpacept with rituximab and lenalidomide achieves a 92% complete response rate in untreated indolent non-Hodgkin lymphoma patients, significantly exceeding the historical 50% response rate for standard treatment, indicating strong anti-tumor activity.
- Patient Response: Among 24 participants, the overall response rate (ORR) of 100% and a one-year progression-free survival (PFS) rate of 91% suggest that this regimen is not only well-tolerated but also effectively prolongs patient survival, enhancing ALX Oncology's competitive position in cancer treatment.
- Research Background Support: Led by Dr. Paolo Strati from The University of Texas MD Anderson Cancer Center, this study further validates the therapeutic potential of blocking CD47 in non-Hodgkin lymphoma characterized by high CD47 expression, potentially laying the groundwork for future immuno-oncology advancements.
- Future Outlook: With ongoing evaluations of minimal residual disease (MRD) eradication rates, ALX Oncology plans to advance evorpacept across multiple cancer indications, showcasing its broad application prospects in oncology treatment.
ALXO.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ALXO
Wall Street analysts forecast ALXO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALXO is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.370
Low
2.00
Averages
3.00
High
4.00
Current: 1.370
Low
2.00
Averages
3.00
High
4.00
Jefferies
NULL -> Buy
initiated
$4
2025-11-13
Reason
Jefferies
Price Target
$4
2025-11-13
initiated
NULL -> Buy
Reason
Jefferies initiated coverage of ALX Oncology with a Buy rating and $4 price target. ALX has strategically focused on two lead programs, Evorpacept in post-ENHERTU HER2+ mBC using prospective CD47 enrichment, supported by "encouraging" gastric data and ALX2004, an ADC with a differentiated design for wider therapeutic window in solid tumors, the analyst tells investors.
UBS
Buy
downgrade
$1
2025-05-21
Reason
UBS
Price Target
$1
2025-05-21
downgrade
Buy
Reason
UBS lowered the firm's price target on ALX Oncology to $1 from $1.20 and keeps a Buy rating on the shares.
H.C. Wainwright
Buy
downgrade
$5 -> $2
2025-05-09
Reason
H.C. Wainwright
Price Target
$5 -> $2
2025-05-09
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on ALX Oncology to $2 from $5 and keeps a Buy rating on the shares. The company announced its decision to discontinue the development of evorpacept in gastric and gastroesophageal cancers based on the FDA's feedback, the analyst tells investors in a research note.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$5
2025-03-07
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$5
2025-03-07
Reiterates
Strong Buy
Reason
See All Ratings
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the significance of the 92% complete response rate in iNHL?
How does evorpacept improve the efficacy of standard iNHL treatments?
Will ALX Oncology's evorpacept combination therapy become the new standard for iNHL?
Can the success of evorpacept in iNHL be replicated in other cancers?